Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Eupraxia reported 52-week data from the highest dose cohorts of EP-104GI in the open-label Phase 1b/2a RESOLVE trial for eosinophilic esophagitis, with 64% of patients (9/14) across Cohorts 5-9 remaining in clinical remission one year after a single administration. Cohort 9 (20x8 mg) showed 66% remission maintenance at 52 weeks, and Cohort 8b showed mean SDI reduction of 3.3 at 36 weeks plus EoEHSS Stage/Grade reductions of -0.26/-0.27. No treatment-related serious adverse events, oropharyngeal candidiasis, adrenal insufficiency, or glucose derangement have been observed, supporting the tolerability profile.
Key figures
- Drug Name
- EP-104GI
- Phase Of Trial
- Phase 1b/2a
- Phase2b interim data
- December 2026
- Cohort9 remission 52wk
- 66% (2 of 3)
- Clinical remission 12wk
- 53% (10/19)
- Clinical remission 24wk
- 78% (14/18)
- Clinical remission 36wk
- 61% (11/18)
- Clinical remission 52wk
- 64% (9/14)
- Cohort8b sdi reduction 36wk
- 3.3
- Eoehss grade reduction 36wk
- -0.27
- Eoehss stage reduction 36wk
- -0.26
- Cohort9 sdi reduction 36 52wk
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.